PharmaJet partners with Diomics to detect SARS-CoV-2 immune response

PharmaJet Logo

Closely-held PharmaJet’s needle-free injection system will be used to deliver Diomics’ Diocheck SARS-CoV-2 visual immune response indicator.

Diomics’ immune response indicator will be injected under the skin using PharmaJet’s Tropis needle-free injection device. The indicator consists of a COVID-19 antigen-containing biopolymer, which causes a skin reaction in individuals who have been exposed to SARS-CoV-2. 

In a statement, Chris Cappello, PharmaJet’s president and CEO, said, “Our needle-free design features a precise and consistent method of delivery to ensure accuracy, in addition to its proven ease of administration in mass immunization campaigns.”

Sign up for the BioTuesdays weekly newsletter

Get the latest news on the healthcare industry’s corporate and clinical developments, executive moves, and market updates. Every Tuesday, in your inbox.